Related Experiment Video

Updated: May 17, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

New avenues for the pharmacological management of type 2 diabetes: an update

Thomas Cuny1, Bruno Guerci, Bertrand Cariou

  • 1University of Nancy I, Department of Endocrinology, University Hospital of Nancy-Brabois, 54511 Vandoeuvre-Les-Nancy, France.

Annales D'Endocrinologie
|October 20, 2012
PubMed

Insights

New oral antidiabetic drugs (OADs) target type 2 diabetes mellitus (T2DM) by addressing insulin resistance and secretion. Emerging therapies like SGLT-2 inhibitors offer novel approaches for glycemic control, with ongoing evaluation of long-term benefits.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus (T2DM) is a global chronic disease with increasing prevalence.
  • Current oral antidiabetic drugs (OADs) target insulin resistance and impaired insulin secretion.
  • Incretin-based therapies, including GLP-1 receptor agonists and DPP-4 inhibitors, modulate incretin hormone action.

Purpose of the Study:

  • To review current and emerging oral antidiabetic drug (OAD) therapies for type 2 diabetes mellitus (T2DM).
  • To discuss novel therapeutic targets for T2DM management.
  • To highlight the role of SGLT-2 inhibitors as advanced OADs.

Main Methods:

  • Review of existing literature on oral antidiabetic drugs.
  • Analysis of pathophysiological targets for T2DM treatment.
  • Discussion of emerging drug classes and their mechanisms.

Main Results:

  • Established OADs address insulin resistance (metformin, thiazolidinediones) and secretion (sulfonylureas, glinides, incretin mimetics).
  • Incretin-based therapies enhance GLP-1 action or preserve endogenous GLP-1.
  • SGLT-2 inhibitors lower HbA1C by promoting glycosuria and induce moderate weight loss.

Conclusions:

  • New OAD development in 2012 focuses on kidney homeostasis, glucagon signaling, and inflammation.
  • SGLT-2 inhibitors represent a significant advancement in T2DM treatment.
  • Long-term evaluation of side effects and clinical benefits of new OADs is crucial.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...